Skip to main content
. 2012 Sep 6;2:110. doi: 10.3389/fonc.2012.00110

Figure 1.

Figure 1

Clotting times for human plasma containing MDA-MB-231, SW480, or SW620 cells. The addition of MDA-MB-231, SW480, and SW620 cells shortened clotting times of plasma in a cell count dependent manner. (A–C) The ability for these cells to coagulate plasma was inhibited with a function-blocking antibody to tissue factor (TF) or Annexin V, and completely abrogated with a Factor Xa inhibitor. (D–F) Human sodium citrate anticoagulated plasma was pretreated with vehicle or the FXa inhibitor rivaroxaban for 5 min at room temperature. MDA-MB-231, SW480, or SW620 cells were pretreated with vehicle, a neutralizing antibody to TF (anti-TF, 50 μg/mL) or the phosphatidylserine binding protein Annexin V (20 μg/mL) for 5 min at room temperature. Cells and plasma were then mixed together for 3 min on a KC4 coagulation analyzer prior to recalcification to 8.3 mM (final concentration). Clotting time experiments were performed in duplicate for each condition and reported as the average. Each experiment was independently repeated 3–9 times. Data are reported as mean ± SEM. *P < 0.05 vs. the absence of cells. Inline graphic P < 0.05 vs. vehicle pretreated cells.